Form 4: Corcept Therapeutics Officer Exercises Options and Engages in Planned Stock Transactions

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics Inc., reported a series of equity transactions including option exercises, stock sales under a 10b5-1 plan, and new restricted stock awards.

Summary

• Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics Inc. (CORT), engaged in multiple equity transactions on June 2 and June 3, 2025.
• On June 2, 2025, Mr. Lyon exercised stock options to acquire 5,000 shares of common stock at an exercise price of $13.56 per share.
• Concurrently on June 2, 2025, Mr. Lyon sold a total of 5,000 shares (4,438 shares at a weighted average price of $77.9663 and 562 shares at a weighted average price of $78.6548) under a pre-arranged 10b5-1 trading plan adopted on August 30, 2024.
• Also on June 2, 2025, Mr. Lyon purchased 749 shares of common stock at $71.68 per share through a purchase plan under the company's 2024 Incentive Award Plan.
• Additionally, on June 2, 2025, Mr. Lyon was granted 749 unvested restricted stock awards with a price of $0, which will vest on the one-year anniversary of the grant date.
• On June 3, 2025, 441 shares were withheld by the Issuer at a price of $71.68 to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Mr. Lyon's direct beneficial ownership of common stock stands at 10,066 shares, which includes 803 shares underlying previously granted unvested restricted stock awards and the newly granted 749 unvested restricted stock awards.
• Mr. Lyon also holds 41,571 unexercised stock options with an exercise price of $13.56, which are fully exercisable.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are sales, they are pre-planned (10b5-1), and there are also new share acquisitions through a purchase plan and restricted stock awards, indicating continued equity participation by the officer.

Positives

• The exercise of stock options indicates the reporting person's continued participation in the company's equity incentive plans.
• The acquisition of 749 shares through a purchase plan and 749 unvested restricted stock awards demonstrates ongoing equity participation and alignment with shareholder interests.

Negatives

• The sale of 5,000 shares, even if pre-planned, represents a reduction in direct ownership by the officer.

Future Outlook

The document does not provide a future outlook for the company, focusing solely on insider equity transactions.

Industry Context

This Form 4 filing details routine insider equity transactions for an officer of a pharmaceutical company. Such transactions are common and often pre-scheduled, providing limited direct insight into broader industry trends or competitive positioning.

Related Party Transactions

• The transactions involve the Reporting Person and the Issuer, which are considered related parties in the context of equity compensation and ownership.

Stakeholder Impact

• Shareholders: The transactions represent a routine change in an officer's direct equity holdings, with sales offset by new acquisitions and option exercises. The 10b5-1 plan suggests no immediate new insight into management's view of the stock.
• Employees: The equity awards and purchase plan are part of the company's incentive structure for its officers.

Next Steps

• The unvested restricted stock awards granted on September 3, 2024, December 2, 2024, March 3, 2025, and June 2, 2025, are expected to vest on their respective one-year anniversaries, provided certain requirements are met.

Key Dates

Keywords

Corcept Therapeutics, CORT, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Awards, 10b5-1 Plan, Equity Transactions, Joseph Douglas Lyon, Officer Stock Sales, Officer Stock Purchases